M. Yilmaz, B. Suleyman, R. Mammadov, D. Altuner, T. Coban, S. Bulut, H. Suleyman, Resid Coskun
{"title":"Role of L-, N- and T-type Calcium Channels in Achieving Maximum Analgesic and Minimum Toxic Effect of Tramadol","authors":"M. Yilmaz, B. Suleyman, R. Mammadov, D. Altuner, T. Coban, S. Bulut, H. Suleyman, Resid Coskun","doi":"10.32383/appdr/179230","DOIUrl":"https://doi.org/10.32383/appdr/179230","url":null,"abstract":"The aim of the study was to investigate the effects of lacidipine, amlodipine and benidipine on the analgesic activity and toxicity of tramadol. Rats (n=6/each group) were divided into five groups as control(CG), tramadol(TRD), lacidipine+tramadol(LTRD), amlodipine+tramadol(ATRD) and benidipine+tramadol(BTRD). Tramadol was administered once at a dose of 50 mg/kg and lacidipine, amlodipin, benidipin were administered at a dose of 4 mg/kg orally, once a day for 10 days. After the animals were sacrificed malondialdehyde(MDA) and total glutathione(tGSH) levels were measured in brain, heart, liver and kidney tissues. Troponin I(Tp I), alanine aminotransferase(ALT), aspartate aminotransferase(AST), blood urea nitrogen(BUN), and creatinine levels were determined in serum. Paw pain thresholds were measured 1 hour before and after drug administration. Analgesic effect of tramadol was increased the most by benidipine, while amlodipine and lacidipine increased it equally. Lacidipine failed to suppress MDA increase and tGSH decrease in brain tissue. Benidipine suppressed MDA increase and tGSH decrease in brain tissue better than amlodipine. All three drugs suppressed cardiac tissue oxidative stress and the release of TP I into the circulation. Lacidipine and amlodipine could not prevent tramadol-induced oxidative stress in liver and kidney tissues, whereas benidipine prevented excessive MDA increase and tGSH decrease. Benidipine significantly suppressed the increase of ALT, AST, BUN, and creatinine. Analgesic activity was 35.1% in TRD, 43.7% in LTRD 50.4% in ATRD and 67,5% in BTRD. Study results show that benidipine and tramadol co-treatment is better than co-treatment with lacidipine or amlodipine in achieving minimal toxic effects and maximum analgesia.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140720748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Iwona Wrześniewska - Wal, J. Pinkas, Mateusz Jankowski
{"title":"Current State of Community Pharmacist-Physician Collaboration — A Cross-sectional Survey Among Pharmacists\u0000in Poland","authors":"Iwona Wrześniewska - Wal, J. Pinkas, Mateusz Jankowski","doi":"10.32383/appdr/183708","DOIUrl":"https://doi.org/10.32383/appdr/183708","url":null,"abstract":"A patient-centered partnership between different healthcare professionals is critical to improving the quality of health services. While the cooperation of physicians, nurses, midwives, and paramedics is well documented, more and more attention is paid to the role of pharmacists in interdisciplinary care. This study aimed to evaluate the pharmacist’s perception of the current state of community pharmacist-physician collaborative working as well as to identify barriers to the implementation of the community pharmacist-physician collaborative working model in Poland. This cross-sectional survey was carried out between October and December 2022 among community pharmacists in Poland. A total number of 1327 pharmacists from one of the largest franchise chain pharmacy networks in Poland were invited to take part in this study. The study questionnaire included 23 questions on the current state of pharmacist-physician collaborative working, the scope of cooperation, barriers to cooperation, and educational and organizational needs. Completed questionnaires were received from 635 pharmacists (response rate of 47.9%). Formal correction of the prescription (91.3%) was the most common cause of pharmacist-physician collaborative working. Moreover, 62.7% of pharmacists indicated that modification of ordered drugs was the reason for pharmacist-physician collaborative working. Only 3.3% of community pharmacists indicated that they collaborate with physicians during the drug review. Lack of IT systems enabling pharmacist-physician collaborative working (67.6%) and lack of recommendations on pharmacist-physician collaborative working (57.3%) were the most common barriers to collaboration with the physician. Pharmacists declare their readiness to cooperate with physicians, but there is a need to strengthen trust between both groups.","PeriodicalId":7135,"journal":{"name":"Acta Poloniae Pharmaceutica - Drug Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140723899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}